The existence of other healthcare problems may perhaps have an affect on using this medicine. Ensure you tell your medical professional When you have some other healthcare challenges, In particular:
butabarbital will lower the level or effect of etonogestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Documentation of allergenic cross-reactivity for barbiturates is restricted. Nonetheless, as a consequence of similarities in chemical composition and/or pharmacologic actions, the opportunity of cross-sensitivity cannot be dominated out with certainty.
These brokers must only be mixed if choice remedy options are inadequate. If merged, Restrict the dosages and length of each and every drug. Take into account therapy modification
butabarbital will lower the extent or impact of ixabepilone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
buprenorphine subdermal implant and butabarbital both equally maximize sedation. Avoid or Use Alternate Drug. Limit use to individuals for whom option treatment method options are insufficient
butabarbital will minimize the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
Contraindicated click here (1)butabarbital will minimize the level or effect of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
fentanyl transdermal and butabarbital both enhance sedation. Steer clear of or Use Alternate Drug. Limit use to clients for whom substitute cure solutions are inadequate
butabarbital will lower the level or outcome of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.
butabarbital, calcium/magnesium/potassium/sodium oxybates. Possibly raises outcomes of the other by pharmacodynamic synergism. Contraindicated. Coadministration with alcohol or sedative hypnotics are contraindicated because of additive CNS despair.
butabarbital will lower the extent or result of dapsone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.
Sure medicines shouldn't be made use of at or throughout the time of having food items or having certain forms of food items because interactions may well come about.
butabarbital will lessen the extent or outcome of guanfacine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Potent or average CYP3A4 inducers significantly decrease guanfacine plasma concentrations and elimination half-lifestyle.